Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 5, pp 406–408 | Cite as

Pharmacokinetics of recombinant interferon alpha-C

  • Ofer Merimsky
  • Menachem Rubinstein
  • Dina Fischer
  • Abraham Danon
  • Samario Chaitchik
Short Communications Pharmacokinetics, Recombinant Interferon Alpha-C

Summary

Recombinant interferon alpha-C (rIFNα-C, Interpharm), is a new type of alpha-interferon that has a specific activity of 1–2×109 units/mg protein. The pharmacokinetics of rIFNα-C were studied in 11 patients with metastatic renal-cell carcinoma. A total of 10 million units IFNα-C were injected intramuscularly and the serum level of IFN was evaluated up to 72 h post-administration. Measurable IFN concentrations appeared in the serum as early as 0.5 h, and levels peaked at 4–6 h (Cmax=53.2±4.6 units/ml). Relatively high levels persisted for 24 h and declined thereafter with an apparent half-life of 3–4 h. The mean area under the serum-concentration curve (AUC) was 1,259±145 units h ml−1, indicating good bioavailability of the preparation from the intramuscular injection.

Keywords

Carcinoma Serum Level Cancer Research Interferon Intramuscular Injection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Billiau A (1981) Interferon therapy: pharmacokinetic and pharmacological aspects. Arch Virol 67: 121Google Scholar
  2. 2.
    Bocci V (1988) Pharmacokinetics of interferons and practical implications. In: Revel M (ed) Clinical aspects of interferons. Kluwer Academic, Boston, p 259Google Scholar
  3. 3.
    Bocci V, Pacini A, Bandinelli L (1982) The role of liver in the catabolism of human alpha and beta interferon. J Gen Virol 60: 397Google Scholar
  4. 4.
    Bornemann LD, Spiegel HE, Dziewanowska ZE (1985) Intravenous and intramuscular pharmacokinetics of recombinant leukocyte A interferon. Eur J Clin Pharmacol 28: 469Google Scholar
  5. 5.
    Gutterman JU, Fine S, Quesada J (1982) Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance and biological effects in cancer patients. Ann Intern Med 96: 549Google Scholar
  6. 6.
    Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH (1983) Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J Infect Dis 148: 335Google Scholar
  7. 7.
    Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142: 1173Google Scholar
  8. 8.
    Mannering GJ, Deloria LB (1986) The pharmacology and toxicology of the interferons: an overview. Annu Rev Pharmacol Toxicol 26: 455Google Scholar
  9. 9.
    Meager A (1987) Quantification of interferons by anti-viral assays and their standardization. In: Clemens MJ, Morris AG, Gearing AJH (eds) Lymphokines and interferons: a practical approach. IRL Press, Oxford, p 129Google Scholar
  10. 10.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer patients. Cancer 47: 207Google Scholar
  11. 11.
    Scott GM (1982) Interferon: pharmacokinetics and toxicity. Phil Trans R Soc Lond B 299: 91Google Scholar
  12. 12.
    Wills RJ, Dennis S, Spiegel HE (1984) Interferon kinetics and adverse reactions after inravenous, intramuscular and subcutaneous injection. Clin Pharmacol Ther 35: 722Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Ofer Merimsky
    • 1
  • Menachem Rubinstein
    • 2
  • Dina Fischer
    • 3
  • Abraham Danon
    • 4
  • Samario Chaitchik
    • 1
  1. 1.Department of OncologyTel-Aviv Sourasky Medical CenterTel-AvivIsrael
  2. 2.Department of VirologyWeizman Institute of ScienceRehovothIsrael
  3. 3.Interpharm Laboratories, Ltd.Ness ZionaIsrael
  4. 4.Department of Clinical PharmacologyBen Gurion University and Soroka Medical CenterBeer ShebaIsrael

Personalised recommendations